Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19073111 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | March 2025 | September 2025 | Allow | 7 | 0 | 1 | No | No |
| 18738089 | (9BETA-H)-PIMARANE MOTHER NUCLEUS DITERPENOID COMPOUND WITH ANTI-COLON CANCER ACTIVITY AND DERIVATIVE THEREOF, AND PREPARATION METHOD THEREOF | June 2024 | October 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18226713 | BIODEGRADABLE DRUG-POLYMER CONJUGATE | July 2023 | August 2025 | Allow | 24 | 1 | 1 | No | No |
| 18273834 | CONTINUOUS PROCESS FOR THE SYNTHESIS OF DIMETHYL CARBONATE OVER A CERIUM-BASED CATALYST FORMULATION | July 2023 | March 2026 | Allow | 32 | 0 | 1 | No | No |
| 17800330 | MACROCYCLIC COMPOUNDS AND USES THEREOF | January 2023 | November 2025 | Allow | 39 | 0 | 0 | No | No |
| 18061810 | USE OF CANNABIDIOL FOR THE TREATMENT OF INSOMNIA ASSOCIATED TO PAIN | December 2022 | February 2026 | Abandon | 39 | 2 | 0 | Yes | No |
| 17984218 | KETO ESTER COMPOSITIONS AND METHODS FOR USING SAME | November 2022 | May 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17983732 | METHODS OF TREATING GLIOBLASTOMA | November 2022 | December 2025 | Abandon | 37 | 2 | 0 | No | No |
| 17961103 | TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | October 2022 | April 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17880397 | Non-Psychoactive Multi-Cannabinoid And Terpene-Based Therapeutic Compositions And Methods Of Their Administration | August 2022 | February 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17758344 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE TARGETING EGFR MUTATION, AS WELL AS THE PREPARATIVE METHOD AND THE USE THEREOF | July 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17789182 | COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | June 2022 | February 2026 | Allow | 44 | 1 | 1 | Yes | No |
| 17757946 | CRYSTAL FORM OF PYRIDOPYRIMIDINE DERIVATIVE AND PREPARATION METHOD THEREOF | June 2022 | December 2024 | Allow | 30 | 0 | 0 | Yes | No |
| 17757944 | POLYCYCLIC COMPOUND ACTING AS KINASE INHIBITOR | June 2022 | November 2025 | Allow | 41 | 1 | 1 | No | No |
| 17787000 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | June 2022 | October 2025 | Allow | 40 | 1 | 1 | No | No |
| 17778828 | ANTICANCER COMPOUND AND MEDICAL USE THEREOF | May 2022 | January 2026 | Abandon | 44 | 1 | 1 | No | No |
| 17774200 | OKN-007 AS A THERAPEUTIC AGENT | May 2022 | August 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17771730 | SYNERGISTIC INHIBITORS OF CREB-MEDIATED GENE TRANSCRIPTION | April 2022 | June 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17659121 | METHODS FOR TREATING BREAST CANCER | April 2022 | November 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17767480 | ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR | April 2022 | July 2025 | Allow | 39 | 0 | 1 | Yes | No |
| 17765169 | Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for Their Preparation and Therapeutic Uses Thereof | March 2022 | November 2025 | Allow | 44 | 1 | 1 | No | No |
| 17760786 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | March 2022 | August 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17681197 | CARBOPLATIN COMPLEX AND PHARMACEUTICAL PREPARATION THEREOF | February 2022 | December 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17638707 | INDOLE CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | February 2022 | July 2025 | Allow | 41 | 0 | 1 | Yes | No |
| 17629976 | EGFR Inhibitor, Composition, and Preparation Method Therefor | January 2022 | September 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17628863 | CONTINUOUS CRYSTALLIZATION OF CANNABINOIDS IN A TUBULAR FLOW REACTOR | January 2022 | October 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17596048 | 3-(2-(HETEROARYL)-PYRIDIN-4-YL)-5-(TRIFLUOROMETHYL)-1,2,4-OXADIAZOLE DERIVATIVES AS HDAC6 INHIBITORS | December 2021 | September 2025 | Allow | 45 | 1 | 0 | Yes | No |
| 17616070 | HECT E3 LIGASE INHIBITORS AND USES THEREOF | December 2021 | July 2025 | Allow | 43 | 1 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner VALLE, ERNESTO works in Art Unit 1623 and has examined 2 patent applications in our dataset. With an allowance rate of 100.0%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.
Examiner VALLE, ERNESTO's allowance rate of 100.0% places them in the 94% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by VALLE, ERNESTO receive 1.00 office actions before reaching final disposition. This places the examiner in the 8% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by VALLE, ERNESTO is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +0.0% benefit to allowance rate for applications examined by VALLE, ERNESTO. This interview benefit is in the 12% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.